ResearcherUniversity of California San DiegoNo recent work listed

Deepak Rohila

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7138-2702; OpenAlex author ID A5059107772. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper

Papers 1

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3645 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tatiana Hurtado de Mendoza · 1 shared paper, 2023 · strength 0.16
- Paper Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreati… DOI 10.1158/0008-5472.can-22-3645 ↗
Shweta Joshi · 1 shared paper, 2023 · strength 0.16
- Paper Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreati… DOI 10.1158/0008-5472.can-22-3645 ↗
Jonathan Weitz · 1 shared paper, 2023 · strength 0.16
- Paper Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreati… DOI 10.1158/0008-5472.can-22-3645 ↗
Andrew M. Lowy · 1 shared paper, 2023 · strength 0.16
- Paper Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreati… DOI 10.1158/0008-5472.can-22-3645 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.